BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/15/2023 12:44:08 AM | Browse: 122 | Download: 317
 |
Received |
|
2022-10-03 23:37 |
|
Peer-Review Started |
|
2022-10-03 23:40 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-10-24 22:51 |
|
Revised |
|
2022-11-25 20:59 |
|
Second Decision |
|
2023-01-12 03:31 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-01-12 18:19 |
|
Articles in Press |
|
2023-01-12 18:19 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-02-07 07:59 |
|
Publish the Manuscript Online |
|
2023-02-15 00:44 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment response in gastric cancer: A prospective pilot study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Daniel Skubleny, Andrea Lin, Saurabh Garg, Ross Mclean, Michael McCall, Sunita Ghosh, Jennifer L Spratlin, Daniel Schiller and Gina Rayat |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Daniel Skubleny, MD, PhD, Doctor, Surgery, University of Alberta, 116 St & 85 Ave, Edmonton T6G 2R3, AB, Canada. skubleny@ualberta.ca |
| Key Words |
CD4; CD8; Galectin-3; Neoadjuvant chemotherapy; Treatment response; Gastric Cancer |
| Core Tip |
In the absence of treatment response, neoadjuvant chemotherapy for gastric cancer may contribute to adverse events without additional survival benefit compared to adjuvant treatment or surgery alone. Identifying patients that are likely to achieve favourable tumour response following neoadjuvant chemotherapy is of critical importance. In this pilot study, we investigate the utility of CD4, CD8, Galectin-3 and E-cadherin molecules in predicting which patients will benefit from neoadjuvant therapy using immunohistochemistry in pre-treatment biopsies. We demonstrate that an elevated ratio between CD4+ and CD8+ lymphocytes is a promising biomarker to predict treatment response to neoadjuvant chemotherapy in locally advanced gastric cancer. |
| Publish Date |
2023-02-15 00:44 |
| Citation |
Skubleny D, Lin A, Garg S, Mclean R, McCall M, Ghosh S, Spratlin JL, Schiller D, Rayat G. Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment response in gastric cancer: A prospective pilot study. World J Gastrointest Oncol 2023; 15(2): 303-317 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i2/303.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i2.303 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
